BBP vs. CNCR

Last updated Apr 2, 2026

Compare and contrast key facts about Virtus LifeSci Biotech Products ETF (BBP) and Loncar Cancer Immunotherapy ETF (CNCR).

BBP and CNCR are both exchange-traded funds (ETFs), meaning they are traded on stock exchanges and can be bought and sold throughout the day. BBP is a passively managed fund by Virtus Investment Partners that tracks the performance of the LifeSci Biotechnology Products Index. It was launched on Dec 17, 2014. CNCR is a passively managed fund by Exchange Traded Concepts that tracks the performance of the Loncar Cancer Immunotherapy Index. It was launched on Oct 13, 2015. Both BBP and CNCR are passive ETFs, meaning that they are not actively managed but aim to replicate the performance of the underlying index as closely as possible.

Performance

BBP vs. CNCR - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Virtus LifeSci Biotech Products ETF (BBP) and Loncar Cancer Immunotherapy ETF (CNCR). The values are adjusted to include any dividend payments, if applicable.

BBP vs. CNCR - Yearly Performance Comparison

	2026 (YTD)
BBP Virtus LifeSci Biotech Products ETF	2.09%
CNCR Loncar Cancer Immunotherapy ETF	0.00%

Returns By Period

BBP

• 1D: 0.80%
• 1M: -0.93%
• YTD: 4.77%
• 6M: 17.96%
• 1Y: 47.40%
• 3Y*: 19.33%
• 5Y*: 9.54%
• 10Y*: 12.85%

CNCR

• 1D: 0.00%
• 1M: 0.00%
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

BBP vs. CNCR - Expense Ratio Comparison

Both BBP and CNCR have an expense ratio of 0.79%.

BBP

Virtus LifeSci Biotech Products ETF

CNCR

Loncar Cancer Immunotherapy ETF

Return for Risk

BBP vs. CNCR — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

BBP

BBP Risk / Return Rank: 85
BBP Sharpe Ratio Rank: 85
BBP Sortino Ratio Rank: 87
BBP Omega Ratio Rank: 77
BBP Calmar Ratio Rank: 90
BBP Martin Ratio Rank: 88

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

BBP vs. CNCR - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Virtus LifeSci Biotech Products ETF (BBP) and Loncar Cancer Immunotherapy ETF (CNCR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	BBP	CNCR	Difference
Sharpe ratio Return per unit of total volatility	1.78	—	—
Sortino ratio Return per unit of downside risk	2.44	—	—
Omega ratio Gain probability vs. loss probability	1.30	—	—
Calmar ratio Return relative to maximum drawdown	3.20	—	—
Martin ratio Return relative to average drawdown	11.83	—	—
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

Sharpe Ratios by Period

	BBP	CNCR	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	1.78	—	—
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.37	—	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.47	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.40	—	—

Dividends

BBP vs. CNCR - Dividend Comparison

Neither BBP nor CNCR has paid dividends to shareholders.

	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
BBP Virtus LifeSci Biotech Products ETF	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.18%	0.00%	1.29%
CNCR Loncar Cancer Immunotherapy ETF	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Drawdowns

BBP vs. CNCR - Drawdown Comparison

The maximum BBP drawdown since its inception was -44.32%, which is greater than CNCR's maximum drawdown of 0.00%. Use the drawdown chart below to compare losses from any high point for BBP and CNCR.

Drawdown Indicators

	BBP	CNCR	Difference
Max Drawdown Largest peak-to-trough decline	-44.32%	0.00%	-44.32%
Max Drawdown (1Y) Largest decline over 1 year	-13.38%	—	—
Max Drawdown (5Y) Largest decline over 5 years	-38.28%	—	—
Max Drawdown (10Y) Largest decline over 10 years	-44.32%	—	—
Current Drawdown Current decline from peak	-3.12%	0.00%	-3.12%
Average Drawdown Average peak-to-trough decline	-12.16%	0.00%	-12.16%
Ulcer Index Depth and duration of drawdowns from previous peaks	3.62%	—	—

Volatility

Volatility by Period

	BBP	CNCR	Difference
Volatility (1M) Calculated over the trailing 1-month period	10.64%	—	—
Volatility (6M) Calculated over the trailing 6-month period	18.02%	—	—
Volatility (1Y) Calculated over the trailing 1-year period	27.02%	0.00%	+27.02%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	26.22%	0.00%	+26.22%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	27.51%	0.00%	+27.51%